Individual and joint effects of metformin and statins on mortality among patients with high‐risk PCa
Updated: Sep 21, 2021
Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Authors: Xiang‐Lin Tan, Jian‐Yu E, Yong Lin, Timothy R. Rebbeck, Shou‐En Lu, Mingyi Shang, William K. Kelly, Anthony D'Amico, Mark N. Stein, Lanjing Zhang, Thomas L. Jang, Isaac Yi Kim, Kitaw Demissie, Anna Ferrari, Grace Lu‐Yao
Background Pre‐clinical studies suggest that metformin and statins may delay prostate cancer (PCa) metastases; however, data in humans are limited. To the best of our knowledge, this is the first human study aimed to quantify the individual and joint effects of statin and metformin use among patients with high‐risk PCa.
Methods This population‐based retrospective cohort study identified patients from the Surveillance, Epidemiology, and End Results (SEER)‐Medicare linked database. Exposure to metformin and statins was ascertained from Medicare Prescription Drug Event files. The association with all‐cause and PCa mortality were evaluated using Cox proportional hazard model with competing causes of death, where propensity scores were used to adjusted imbalances in covariates across groups.
Results Based on 12 700 patients with high‐risk PCa, statin alone or in combination with metformin was significantly associated with reduced all‐cause mortality (Hazard Ratio [HR]: 0.89; 95% Confidence Interval [CI]: 0.83, 0.96; and HR: 0.75; 95% CI, 0.67‐0.83, respectively) and PCa mortality (HR, 0.80; 95% CI: 0.69, 0.92) and 0.64; 95% CI, d 0.51‐0.81, respectively. The effects were more pronounced in post‐diagnostic users: combination use of metformin/statins was associated with a 32% reduction in all‐cause mortality (95% CI, 0.57‐0.80), and 54% reduction in PCa mortality (95% CI, 0.30‐0.69). No significant association of metformin alone was observed with either all‐cause mortality or PCa mortality.
Conclusions Statin use alone or in combination with metformin was associated with lower all‐cause and PCa mortality among high‐risk patients, particularly in post‐diagnostic settings; further studies are warranted.
Please contact us if you are having difficulty accessing the full PDF of this or any MADCaP publication.